These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. High-throughput screens based on NAD(P)H depletion. Glieder A; Meinhold P Methods Mol Biol; 2003; 230():157-70. PubMed ID: 12824579 [No Abstract] [Full Text] [Related]
4. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant. Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991 [TBL] [Abstract][Full Text] [Related]
6. High-throughput screening of mutant alpha-amylase libraries for increased activity at 129 degrees C. Berk H; Lebbink RJ Methods Mol Biol; 2003; 230():127-35. PubMed ID: 12824575 [No Abstract] [Full Text] [Related]
7. Sensitive assay for laboratory evolution of hydroxylases toward aromatic and heterocyclic compounds. Wong TS; Wu N; Roccatano D; Zacharias M; Schwaneberg U J Biomol Screen; 2005 Apr; 10(3):246-52. PubMed ID: 15809320 [TBL] [Abstract][Full Text] [Related]
8. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. Peters MW; Meinhold P; Glieder A; Arnold FH J Am Chem Soc; 2003 Nov; 125(44):13442-50. PubMed ID: 14583039 [TBL] [Abstract][Full Text] [Related]
9. Electron transfer in flavocytochrome P450 BM3: kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase. Roitel O; Scrutton NS; Munro AW Biochemistry; 2003 Sep; 42(36):10809-21. PubMed ID: 12962506 [TBL] [Abstract][Full Text] [Related]
10. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium. Urlacher VB; Schmid RD Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074 [No Abstract] [Full Text] [Related]
11. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. van Vugt-Lussenburg BM; Stjernschantz E; Lastdrager J; Oostenbrink C; Vermeulen NP; Commandeur JN J Med Chem; 2007 Feb; 50(3):455-61. PubMed ID: 17266197 [TBL] [Abstract][Full Text] [Related]
12. Engineering cytochrome P450 monooxygenase CYP 116B3 for high dealkylation activity. Liu L; Schmid RD; Urlacher VB Biotechnol Lett; 2010 Jun; 32(6):841-5. PubMed ID: 20213524 [TBL] [Abstract][Full Text] [Related]
13. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options. Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351 [TBL] [Abstract][Full Text] [Related]
14. Laboratory evolution of cytochrome p450 BM-3 monooxygenase for organic cosolvents. Wong TS; Arnold FH; Schwaneberg U Biotechnol Bioeng; 2004 Feb; 85(3):351-8. PubMed ID: 14748091 [TBL] [Abstract][Full Text] [Related]
15. Bacterial expression and purification of the Arabidopsis NADPH-cytochrome P450 reductase ATR2. Hull AK; Celenza JL Protein Expr Purif; 2000 Apr; 18(3):310-5. PubMed ID: 10733884 [TBL] [Abstract][Full Text] [Related]
16. Screening and selection strategies for disulfide isomerase activity. Lafond R; Zhan X; Georgiou G Methods Mol Biol; 2003; 230():239-57. PubMed ID: 12824588 [No Abstract] [Full Text] [Related]
17. Selection of heat-stable Clostridium cellulovorans cellulases after in vitro recombination. Murashima K; Doi RH Methods Mol Biol; 2003; 230():231-7. PubMed ID: 12824587 [No Abstract] [Full Text] [Related]